Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063865 | 1.00 | KDM1A (0.35) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL20072838 | 0.89 | HDAC4 (0.39) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL21306759 | 0.88 | KAT6A (0.36) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL20063687 | 0.83 | NFKB1 (0.38) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL21838571 | 0.83 | CTSB (0.36) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL20063878 | 0.81 | KDM1A (0.39) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL20063868 | 0.81 | KDM1A (0.39) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL20063881 | 0.80 | KDM1A (0.38) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL20063892 | 0.80 | KDM1A (0.38) | KDM1AMAOBMAOANFKB1NFKB2 | |
| SCHEMBL20063891 | 0.79 | KDM1A (0.37) | KDM1AMAOBMAOANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | KDM1A 2873/4885MAOB 2113/4885MAOA 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.